Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

US pharma major Eli Lilly (NYSE: LLY) spotlighted new safety and efficacy data for its investigational oral GLP-1 therapy ...

LifeMD is a fast-growing, profitable telehealth company with strong partnerships. Click here to read why LFMD stock is a Buy.

Sciwind Biosciences has shared late-stage trial data for its injectable GLP-1 therapy, signaling Chinese firms’ intensifying ...

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

The timing is also interesting. GLP-1s are Novo Nordisk's biggest and fastest-growing revenue stream, and competition is heating up. Eli Lilly's Zepbound is gaining traction, compounded access is ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate ...